Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8176 to 8190 of 8973 results

  1. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued Reference number: GID-TA10418

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued Reference number: GID-TA10583

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    Discontinued Reference number: GID-TA10906

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    In development Reference number: GID-TA10747 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  6. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  7. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    In development Reference number: GID-TA11759 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]

    In development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]

    In development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)

    This guidance has been updated and replaced by NICE HealthTech guidance 668.

    Withdrawn guidance

  11. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  12. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  13. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  14. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

    NICE guideline
    Discontinued

  15. Preterm labour and birth - predicting preterm birth

    Discontinued Reference number: GID-NG10384

    NICE guideline
    Discontinued